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However, according to the study by Karwowski 
et al,6 published in the current issue of the Polish 
Archives of Internal Medicine, the mortality benefit 
of the patent IRA before primary PCI for STEMI 
may be limited only to patients with STEMI relat‑
ed to stenosis or occlusion of the left anterior de‑
scending artery (LAD). This observation is quite 
obvious as the possible benefits of IRA patency 
are especially pronounced in high ‑risk patients 
with a large area of the myocardium at risk. These 
high ‑risk population includes predominantly pa‑
tients with LAD ‑related STEMI, because the LAD 
supplies a large proportion of the left ventricu‑
lar myocardium. 
In line with the above findings, previous stud‑
ies confirmed that mortality benefits from phar‑
macologically induced early reperfusion in pa‑
tients with STEMI using intravenous abciximab 
are limited only to high ‑risk individuals, includ‑
ing those with anterior ‑wall STEMI.7 On the oth‑
er hand, the lack of clear mortality benefits from 
the patent IRA in patients with STEMI related to 
the left circumflex artery (LCx) and the right coro‑
nary artery (RCA) cannot be explained by the dif‑
ferences in the risk among the groups as the long‑
‑term mortality and prevalence of Killip class of 3 
or higher on admission were quite comparable.6 
As suggested by Karwowski et al,6 the lack of 
the expected benefit is probably associated with 
a lower area of the myocardium at risk in patients 
with STEMI related to the LCx or RCA compared 
with those with LAD‑related STEMI. However, de‑
spite the enrollment of over 4500 patients with 
STEMI, the results of subgroup analyses should be 
interpreted with caution, and strong statements 
concerning the lack of benefit should be avoided. 
Also, quite surprisingly, patients with TIMI grade 
1 flow were included in the group with total oc‑
clussion. In contrast, most of the previous studies 
compared patients with TIMI grade 0/1 flow (oc‑
cluded artery) versus 2/3 flow (patent artery).1-4 
This year, we are celebrating the 40th anniversary 
of the first successful percutaneous coronary in‑
tervention (PCI) performed by Andreas Grüntzig 
in September 1977. Five years later, the first suc‑
cessful PCI in acute ST ‑segment elevation myo‑
cardial infarction (STEMI) was conducted by Jür‑
gen Meyer. Since then, a rapid development in 
the procedural technique and concomitant phar‑
macotherapy has been observed, leading to a re‑
duction in mortality of patients presenting with 
STEMI. Despite this progress, the time from 
symptom onset to successful reperfusion and 
the preprocedural patency of the infarct ‑related 
artery (IRA) still remain important determinants 
of outcomes in patients with STEMI.1-4
The presence of the patent IRA, frequently de‑
fined as the Thrombolysis in Myocardial Infarc‑
tion (TIMI) flow grade 2/3, before primary PCI 
for STEMI, was shown to be associated with im‑
proved short‑ and long ‑term mortality rates.1,3,4 
The mechanism underlying the observed surviv‑
al benefit might be related to less pronounced 
ischemia in the setting of preserved blood flow 
and oxygen supply. Also, achievement of sponta‑
neous or pharmacologically induced early reper‑
fusion may reduce the duration of ischemia (by 
early restoration of flow) and thus prevent irre‑
versible myocardial injury.2 In addition, the pres‑
ence of the patent IRA may indicate lower throm‑
bus load and better visualization of the vessel.1 
Thus, it may facilitate the procedure by allowing 
a better selection of stent size or length and re‑
ducing the risk of complications, including dis‑
tal embolization. As a result, initial IRA patency 
is frequently associated with complete reperfu‑
sion after primary PCI not only on the epicardial 
level (postprocedural TIMI grade 3 flow) but also 
on the microcirculation level (myocardial blush 
grade 3, complete ST ‑segment resolution).5 Im‑
portantly, the achievement of full reperfusion 
on both levels is the main goal of primary PCI.
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mortality rates were comparable between patients 
with and without the occluded IRA before PCI.6,13 
However, Karwowski et al14 stressed the possible 
impact of LCx occlusion on in ‑hospital mortality. 
It might be related to some difficulty in detection 
of LCx ‑related ischemia by standard 12 ‑lead elec‑
trocardiogram (ECG) and possible prolongation 
of time to reperfusion. On the other hand, in pa‑
tients with inconclusive electrocardiogram results 
and signs of ongoing myocardial ischemia, current 
guidelines strongly recommend the recording of 
additional leads (V7–V9 and V3R–V4R).
14 Also, rap‑
id “rule ‑in” and “rule ‑out” of MI is possible using 
high ‑sensitive cardiac troponin assays.14 Impor‑
tantly, it may result in reduced delay to coronary 
angiography and PCI in patients with NSTEMI. 
Thus, the results of the study conducted in 2008 
may not be applicable to current clinical practice. 
Similarly to the STEMI group, no data on ad‑
junctive pharmacotherapy were provided. Re‑
sults of the ACUITY study have suggested that 
administration of unfractionated heparin, P2Y12 
inhibitors, or abciximab was associated with low‑
er rates of the occluded IRA at baseline.13 Howev‑
er, routine pretreatment with P2Y12 inhibitors in 
patients with NSTEMI, especially those with low‑
‑to ‑intermediate risk, is not recommended. It is 
related to the lack of clear clinical benefit and el‑
evated risk of bleeding in case of urgent coronary 
artery bypass grafting related to pretreatment.11,14
Despite a limited mortality benefit in some 
subgroups of patients, early IRA patency will be 
still welcomed by numerous interventional car‑
diologists before conducting PCIs for acute MI. It 
may be potentially promoted by early pharmaco‑
therapy. However, early pharmacotherapy strate‑
gies should be adjusted for clinical presentation 
(STEMI, NSTEMI), logistics, and both ischemic 
and bleeding risk profiles.11 Optimization of phar‑
macotherapy should be accompanied by continu‑
ous efforts to reduce time from symptom onset 
to successful reperfusion. Importantly, as sug‑
gested by Karwowski et al,6 even the presence of 
the patent IRA does not mean the best long ‑term 
prognosis.15 Thus, improvement of each stage of 
MI treatment (pre‑, in‑, and post ‑hospital stages) 
still seems to be justified to improve outcomes.11
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